Iterum Therapeutics Plc(OTC) ITRM

Current Price$0.00

Market CapN/A

Since IPO (2018)-100%

5 Year-100%

1 Year+0%

1 Month-99%

Iterum Therapeutics Plc last closing stock price
Metric	Price	Date
Last close	USD 0.00	2018-01-11

Iterum Therapeutics Plc stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-90%	USD 0.00	2017-12-27
1 month	-99%	USD 0.00	2017-05-16
3 month	-99%	USD 0.00	2017-05-16
Year to date	-90%	USD 0.00	2017-12-27
1 year	+0%	USD 0.00	2016-12-09
3 year	-99%	USD 0.00	2014-11-04
5 year	-99.87%	USD 0.00	2012-07-27
Since inception	-99.98%	USD 192.75	2018-05-25

Iterum Therapeutics Plc Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$390.00K

Net Income (TTM)

-$26.96M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 20, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 20, 2026

ITRM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Iterum Therapeutics Plc

Iterum develops medicines for bacterial infections that resist common treatments. Its main product helps women with urinary tract infections who lack other options. The company aims to fill gaps where existing antibiotics no longer work.

What’s in the Medicine Cabinet?

ORLYNVAH (oral sulopenem): Treats urinary tract infections in adult women with few other oral antibiotic choices. (0% of revenue as of Q2 2025)
IV sulopenem: In development for more severe urinary and abdominal infections. (0% of revenue as of Q2 2025)

Growth Spurts and Strategic Moves

FDA approved ORLYNVAH for U.S. use in October 2024.
Signed exclusive U.S. commercialization deal with EVERSANA in June 2025.
Secured manufacturing partnership with ACS Dobfar in July 2025.
Raised capital through direct and rights offerings in August 2024 and April 2025.
Exploring licensing or sale of sulopenem rights as of mid-2025.

Why Iterum Is a Bit Different

Iterum operates with a small team and outsources manufacturing and sales. It holds exclusive global rights to its main drug through a license from Pfizer. The company targets patients with few treatment options due to antibiotic resistance.

Five Things You Need to Know

Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
Net loss was $7 million in Q2 2025, 30% greater than Q2 2024.
Cash and cash equivalents were $13 million as of June 30, 2025.
Operating cash outflow improved 25% year-over-year for Q2 2025.

Bottom Line

Iterum focuses on new antibiotics for hard-to-treat infections. Its future depends on successful product launches and careful cash management.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Dublin, 2, IE

ITRM Financials

Key Financial Metrics (TTM)

Gross Margin

-171.28%

Operating Margin

-4261.79%

Net Income Margin

-5225.38%

Return on Equity

442.32%

Return on Capital

-45.10%

Return on Assets

-62.70%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$668.00K

Operating Income

-$20.29M

EBITDA

-$23.07M

Operating Cash Flow

-$19.91M

Capital Expenditure

-$14.57K

Free Cash Flow

-$19.93M

Cash & ST Invst.

$11.00M

Total Debt

$33.74M

Iterum Therapeutics Plc Performance Analysis

Iterum Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	N/A
Q1	2025-03-31	N/A
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A

Iterum Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	16.7%
Q1	2025-03-31	44.0%
Q2	2025-06-30	-14.3%
Q3	2025-09-30	-25.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2025YOY CHG

Revenue

$390.00K

N/A

Gross Profit

$370.00K

N/A

Gross Margin

94.87%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$8.98M

-47.3%

EBITDA

-$8.05M

-50.2%

Quarterly Fundamentals

Name

Q3 2025YOY CHG

Total Cash

$11.00M

-24.1%

Total Debt

$33.74M

+50.4%

Accounts Receivable

$546.00K

+99.3%

Inventory

$1.15M

N/A

Long Term Debt

$33.45M

+283.3%

Short Term Debt

$281.00K

-98.0%

Return on Assets

-62.70%

N/A

Return on Invested Capital

-63.75%

N/A

Free Cash Flow

-$7.86M

-194.2%

Operating Cash Flow

-$7.85M

-193.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

INTSIntensity Therapeutics, Inc.

INTSIntensity Therapeutics, Inc.$4.41+0.23%

IBIOiBio, Inc.

IBIOiBio, Inc.$1.37-3.16%

RLYBRallybio Corporation

RLYBRallybio Corporation$16.82-0.53%

PLURPluri Inc.

PLURPluri Inc.$1.85-5.13%

ANTXAN2 Therapeutics, Inc.

ANTXAN2 Therapeutics, Inc.$4.86-2.81%

BOLDBoundless Bio, Inc.

BOLDBoundless Bio, Inc.$2.49+0.40%

SONNSonnet BioTherapeutics Holdings, Inc.

SONNSonnet BioTherapeutics Holdings, Inc.$1.26-59.35%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.21-0.00%

FFord Motor Company

FFord Motor Company$14.42+0.01%

TET1 Energy Inc.

TET1 Energy Inc.$6.08-0.00%

MARAMara Holdings

MARAMara Holdings$12.48+0.02%

JOBYJoby Aviation

JOBYJoby Aviation$7.67+0.00%

RIGTransocean

RIGTransocean$5.31+0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.59+0.01%

Questions About ITRM

What is the current price of Iterum Therapeutics Plc?

Iterum Therapeutics Plc is trading at N/A per share.

What is the 52-week range for Iterum Therapeutics Plc?

Over the past 52 weeks, Iterum Therapeutics Plc has traded between N/A and N/A.

How much debt does Iterum Therapeutics Plc have?

Iterum Therapeutics Plc total debt is unavailable.

How much cash does Iterum Therapeutics Plc have on hand?

Iterum Therapeutics Plc does not have cash on hand data available.

What is Iterum Therapeutics Plc’s dividend yield?

Iterum Therapeutics Plc does not currently have a dividend yield.

Iterum Therapeutics Plc(OTC) ITRM

Iterum Therapeutics Plc Financials at a Glance

ITRM News

ITRM Reports Results

Why Iterum Therapeutics Stock Is Crashing Today

Why Iterum Therapeutics Stock Soared Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Iterum Therapeutics Plc

What’s in the Medicine Cabinet?

Growth Spurts and Strategic Moves

Why Iterum Is a Bit Different

Five Things You Need to Know

Bottom Line

ITRM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Iterum Therapeutics Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ITRM

What is the current price of Iterum Therapeutics Plc?

What is the 52-week range for Iterum Therapeutics Plc?

How much debt does Iterum Therapeutics Plc have?

How much cash does Iterum Therapeutics Plc have on hand?

What is Iterum Therapeutics Plc’s dividend yield?

Premium Investing Services